LTRN: Lantern Pharma Inc. Stock

by  •  • Comments Off on LTRN: Lantern Pharma Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 41.95
Enterprise Value ($M) 33.85
Book Value ($M) 26.60
Book Value / Share 2.47
Price / Book 1.58
NCAV ($M) 26.23
NCAV / Share 2.43
Price / NCAV 1.60

Profitability (mra)
Return on Invested Capital (ROIC) -0.71
Return on Assets (ROA) -0.44
Return on Equity (ROE) -0.47

Liquidity (mrq)
Quick Ratio 8.31
Current Ratio 8.31

Balance Sheet (mrq) ($M)
Current Assets 29.92
Assets 30.29
Liabilities 3.70
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income 0.00
Net Income 0.00

Cash Flow Statement (mra) ($M)
Cash From Operations 0.00
Cash from Investing 0.00
Cash from Financing 0.00

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
2024-03-01 13D/A Bios Equity Partners, LP 11.80 -13.83
2024-02-14 13G/A ProPhase Labs, Inc. 5.80 -30.64

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-11-07 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 ☐ TRANSITION REPO
2024-08-08 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 ☐ TRANSITION REPORT PU
2024-05-09 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT P
2024-03-18 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT PURSUA

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2025-03-07 4,937 26,524 18.61
2025-03-06 8,917 33,772 26.40
2025-03-05 4,566 23,547 19.39
2025-03-04 26,957 65,010 41.47

(click for more detail)

Similar Companies
LPTX – Leap Therapeutics, Inc. LQDA – Liquidia Corporation
LSTA – Lisata Therapeutics, Inc. MBIO – Mustang Bio, Inc.
MBRX – Moleculin Biotech, Inc.


Financial data and stock pages provided by
Fintel.io